Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis

被引：59
作者：
Mathew, Veena [1 ]
Wang, Annabel K. [1 ,2 ]
机构：
[1] Univ Calif Irvine, Dept Neurol, UCI ALS & Neuromuscular Ctr, Orange, CA 92668 USA
[2] Tibor Rubin VA Med Ctr, Neurol Sect, Long Beach, CA USA
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2019年 / 13卷
关键词：
antisense oligonucleotide; familial amyloid polyneuropathy; Inotersen; mRNA; RNase H; ANTISENSE OLIGONUCLEOTIDE; LIVER-TRANSPLANTATION; MOLECULAR-MECHANISMS; POLYNEUROPATHY; DIFLUNISAL; THERAPY; GENE;
D O I：
10.2147/DDDT.S162913
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Hereditary transthyretin amyloidosis is a fatal autosomal dominant disorder characterized by deposition of transthyretin amyloid into the peripheral nervous system, heart, kidney, and gastrointestinal tract. Previous treatments using liver transplantation and small molecule stabilizers were not effective in stopping disease progression. Inotersen, a 2'-O-methyoxyethyl-modified antisense oligonucleotide, which acts by reducing the production of transthyretin, was recently demonstrated to improve disease course and quality of life in early hereditary transthyretin amyloidosis polyneuropathy in a 15-month Phase III study.
引用
收藏
页码：1515 / 1525
页数：11
相关论文
共 44 条
  • [1] Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides
    Ackermann, Elizabeth J.
    Guo, Shuling
    Benson, Merrill D.
    Booten, Sheri
    Freier, Sue
    Hughes, Steven G.
    Kim, Tae-Won
    Kwoh, T. Jesse
    Matson, John
    Norris, Dan
    Yu, Rosie
    Watt, Andy
    Monia, Brett P.
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2016, 23 (03): : 148 - 157
  • [2] Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy
    Ackermann, Elizabeth J.
    Guo, Shuling
    Booten, Sheri
    Alvarado, Luis
    Benson, Merrill
    Hughes, Steve
    Monia, Brett P.
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2012, 19 : 43 - 44
  • [3] Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
    Adams, D.
    Gonzalez-Duarte, A.
    O'Riordan, W. D.
    Yang, C. -C.
    Ueda, M.
    Kristen, A. V.
    Tournev, I.
    Schmidt, H. H.
    Coelho, T.
    Berk, J. L.
    Lin, K. -P.
    Vita, G.
    Attarian, S.
    Plante-Bordeneuve, V.
    Mezei, M. M.
    Campistol, J. M.
    Buades, J.
    Brannagan, T. H., III
    Kim, B. J.
    Oh, J.
    Parman, Y.
    Sekijima, Y.
    Hawkins, P. N.
    Solomon, S. D.
    Polydefkis, M.
    Dyck, P. J.
    Gandhi, P. J.
    Goyal, S.
    Chen, J.
    Strahs, A. L.
    Nochur, S. V.
    Sweetser, M. T.
    Garg, P. P.
    Vaishnaw, A. K.
    Gollob, J. A.
    Suhr, O. B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) : 11 - 21
  • [4] A PECULIAR FORM OF PERIPHERAL NEUROPATHY - FAMILIAR ATYPICAL GENERALIZED AMYLOIDOSIS WITH SPECIAL INVOLVEMENT OF THE PERIPHERAL NERVES
    ANDRADE, C
    [J]. BRAIN, 1952, 75 (03) : 408 - 427
  • [5] Pharmacology of Antisense Drugs
    Bennett, C. Frank
    Baker, Brenda F.
    Nguyen Pham
    Swayze, Eric
    Geary, Richard S.
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 57, 2017, 57 : 81 - 105
  • [6] Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
    Benson, M. D.
    Waddington-Cruz, M.
    Berk, J. L.
    Polydefkis, M.
    Dyck, P. J.
    Wang, A. K.
    Plante-Bordeneuve, V.
    Barroso, F. A.
    Merlini, G.
    Obici, L.
    Scheinberg, M.
    Brannagan, T. H., III
    Litchy, W. J.
    Whelan, C.
    Drachman, B. M.
    Adams, D.
    Heitner, S. B.
    Conceicao, I.
    Schmidt, H. H.
    Vita, G.
    Campistol, J. M.
    Gamez, J.
    Gorevic, P. D.
    Gane, E.
    Shah, A. M.
    Solomon, S. D.
    Monia, B. P.
    Hughes, S. G.
    Kwoh, T. J.
    McEvoy, B. W.
    Jung, S. W.
    Baker, B. F.
    Ackermann, E. J.
    Gertz, M. A.
    Coelho, T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) : 22 - 31
  • [7] Antisense oligonucleotide therapy for TTR amyloidosis
    Benson, M. D.
    Pandey, S.
    Witchell, D.
    Jazayeri, A.
    Siwkowski, A.
    Monia, B.
    Kluve-Beckerman, B.
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2011, 18 : 60 - 60
  • [8] The molecular biology and clinical features of amyloid neuropathy
    Benson, Merrill D.
    Kincaid, John C.
    [J]. MUSCLE & NERVE, 2007, 36 (04) : 411 - 423
  • [9] Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy
    Benson, Merrill D.
    Dasgupta, Noel R.
    Rissing, Stacy M.
    Smith, Jessica
    Feigenbaum, Harvey
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2017, 24 (04): : 219 - 225
  • [10] Liver transplantation and transthyretin amyloidosis
    Benson, Merrill D.
    [J]. MUSCLE & NERVE, 2013, 47 (02) : 157 - 162
12345